BOLD
Boundless Bio, Inc.
NASDAQ · Healthcare · Biotechnology · US
$2.87
+0.00%Year over year
Reported trailing growth
- Revenue
- —
- EBITDA
- +12.8%
- EBIT
- +4.7%
- EPS
- +4.3%
- Free cash flow
- -0.9%
- Operating cash flow
- -1.9%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- +20.3%
Three-year CAGR
- Revenue
- —
- EBITDA
- +11.4%
- EBIT
- +13.3%
- Net income
- +11.0%
- EPS
- +32.5%
- Free cash flow
- +25.5%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026